Sat, Jan 31, 2015, 12:38 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

OncoSec Medical Incorporated Message Board

  • madipbart madipbart Dec 16, 2013 6:01 PM Flag

    Email From Ms. Chan!!!!

    Hi Phil,

    I'm sure you saw the press release today. I suggest that you don't get
    caught up in the message board conspiracy theorists, as you can see, the
    person who made assumptions that our data must be "Terrible" ended up
    apologizing on the board for misinforming everyone.

    Currently, the standard of care for late stage melanoma patients is
    Yervoy/Zelboraf (this has changed, as it used to be chemotherapy). With
    the improved response rates seen so far with Anti PD-1 (and without the
    toxicity that comes with Yervoy/Zelboraf), it has been predicted by many
    in the scientific field that Anti-PD-1 will become the new standard of
    care (it was just designated by the FDA as 'breakthrough status' - meaning
    the FDA will do an accelerated review of it.

    The thing is, you're seeing an average response rate of about 35% of
    Anti-PD 1, which means there's still about 65% who are non-responders.
    OncoSec added a research study to see if ImmunoPulse can turn non
    responding cells to responding cells. The data so far has been
    encouraging.

    So while we are moving forward with the development of ImmunoPulse, we
    also feel we are at the right time, right place with our current strategy
    to explore ImmunoPulse as a combination approach. The melanoma landscape
    is quickly changing, and we have the right people on board and are
    positioning ourselves to be competitive in this space.

    Best,

    Amy

    Ms. Chan,

    I noticed that the timeline has changed and excludes potential dates for
    trial results. It has been mentioned that there is a bait and switch
    going on. The person believes results are "TERRIBLE" because Oncosec is
    turning their attention to solid tumors instead of skin cancer. I own
    25,000 shares and I need a little transparency. Why did the timeline
    change? Why the focus on PD-1 when we are waiting for results for
    melanoma, merkel cell, etc. Are results that bad?

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
ONCS
0.360.00(-1.37%)Jan 30 3:58 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Boot Barn Holdings, Inc.
NYSEFri, Jan 30, 2015 4:02 PM EST
Visa Inc.
NYSEFri, Jan 30, 2015 4:00 PM EST